ZHANG Research TeamNano Biomedicine Lab
Lu Zhang#, Di Jing#, Nian Jiang, Tatu Rojalin, Christopher M. Baehr, Dalin Zhang, Wenwu Xiao, Yi Wu, Zhaoqing Cong, Jian Jian Li, Yuanpei Li, Lei Wang*, Kit S. Lam*. Transformable peptide nanoparticles arrest HER2 signalling and cause cancer cell death in vivo. Nature Nanotechnology 2020, 15 (2), 145-153. (IF: 40.523) https://www.nature.com/articles/s41565-019-0626-4
2022 1. Di Jing, Nian Jiang, Fengyi Wang, Chunping Mao, Shujun Han, Pui Yan Ho, Wenwu Xiao, Yuanpei Li, Jian-Jian Li, Lu Zhang* (co-corresponding), Kit S Lam*. Nanoradiosensitizer with good tissue penetration and enhances oral cancer radiotherapeutic effect. Biomaterials 2022, 289, 121769. (IF: 15.304) https://www.sciencedirect.com/science/article/pii/S0142961222004094
2. Lu Zhang*, Ruonan Bo, Yi Wu, Longmeng Li, Zheng Zhu, Ai-Hong Ma, Wenwu Xiao, Yanyu Huang, Tatu Rojalin, Xingbin Yin, Chunping Mao, Fengyi Wang, Yongheng Wang, Hongyong Zhang, Kelmen E. Low, Kiana Lee, Yousif Ajena, Di Jing, Dalin Zhang, Christopher M. Baehr, Ruiwu Liu, Lei Wang*, Yuanpei Li*, Kit S. Lam*. Programmable Bispecific Nano-immunoengager That Captures T Cells and Reprograms Tumor Microenvironment. Nano Letters, 2022, 22 (17): 6866–6876. (Supplementary Cover, IF: 12.262) https://pubs.acs.org/doi/10.1021/acs.nanolett.2c00582
Supplementary Cover 3. Zhiqin Zhang, Kaixin Wang, Manting Liu, Panxiang Hu, Yuchen Xu, Dongge Yin, Yuchang Yang, Xiaoxv Dong, Changhai Qu, Lu Zhang* (co-corresponding), Jian Ni*, Xingbin Yin*. Phototherapeutic effect of transformable peptides containing pheophorbide a on colorectal cancer. Drug Delivery, 2022, 29 (1):1608-1619. (IF: 6.819) https://pubmed.ncbi.nlm.nih.gov/35612320/
2021 4. Lu Zhang, Yi Wu, Xingbin Yin, Zheng Zhu, Tatu Rojalin, Wenwu Xiao, Dalin Zhang, Yanyu Huang, Longmeng Li, Christopher M. Baehr, Xingjian Yu, Yousif Ajena, Yuanpei Li, Lei Wang*, Kit S. Lam*. Tumor Receptor-Mediated In Vivo Modulation of the Morphology, Phototherapeutic Properties, and Pharmacokinetics of Smart Nanomaterials. ACS Nano 2021, 15 (1), 468-479. (IF: 18.027) https://pubs.acs.org/doi/10.1021/acsnano.0c05065?fig=tgr1&ref=pdf
5. Pei-Pei Yang#, Yi-Jing Li#, Yan Cao#, Lu Zhang, Jia-Qi Wang, Zi-Wei Lai, Kuo Zhang, Diedra Shorty, Wenwu Xiao, Hui Cao, Lei Wang*, Hao Wang*, Ruiwu Liu*, Kit S. Lam*. Rapid discovery of self-assembling peptides with one-bead one-compound peptide library. Nature Communications 2021, 12, 4494. (IF: 17.694) https://www.nature.com/articles/s41467-021-24597-5
6. Christopher M. Baehr, Lu Zhang, Yi Wu, Andras Domokos, Wenwu Xiao, Lei Wang, Kit S.Lam*. Transformable amyloid-beta mimetic peptide amphiphiles for lysosomal disruption in non-small cell lung cancer. Biomaterials 2021, 277, 121078. (IF: 15.304) https://www.sciencedirect.com/science/article/pii/S0142961221004348
2020 7. Lu Zhang#, Di Jing#, Nian Jiang, Tatu Rojalin, Christopher M. Baehr, Dalin Zhang, Wenwu Xiao, Yi Wu, Zhaoqing Cong, Jian Jian Li, Yuanpei Li, Lei Wang*, Kit S. Lam*. Transformable peptide nanoparticles arrest HER2 signalling and cause cancer cell death in vivo. Nature Nanotechnology 2020, 15 (2), 145-153. (IF: 40.523) https://www.nature.com/articles/s41565-019-0626-4
8. Hao Wu#, Lu Zhang#(co-first), Jinfan Yang, Ruonan Bo, Hongxu Du, Kai Lin, Dalin Zhang, Mythili Ramachandran, Yingbin Shen, Yangxi Xu, Xiangdong Xue, Zhao Ma, Aaron Raymond Lindstrom, Randy Carney, Tzu-Yin Lin, Yuanpei Li. Rotatable Aggregation-Induced-Emission/Aggregation Caused-Quenching Ratio Strategy for Real-Time Tracking Nanoparticle Dynamics. Advanced Functional Materials 2020, 30 (15), 1910348. (IF: 19.924) https://onlinelibrary.wiley.com/doi/10.1002/adfm.201910348
9. Zhaoqing Cong, Lu Zhang, Si-Qi Ma, Kit S.Lam, Fei-Fei Yang*, YongHong Liao*. Size-Transformable Hyaluronan Stacked Self-Assembling Peptide Nanoparticles for Improved Transcellular Tumor Penetration and Photo-Chemo Combination Therapy. ACS Nano 2020, 14 (2), 1958-1970. (IF: 18.027) https://pubs.acs.org/doi/10.1021/acsnano.9b08434
10. Lu Zhang#, Hao Wu#, Yuanpei Li*, Kit S. Lam*. Reversible Cross-Linked Polymeric Micelles for Drug Delivery. Elsevier, 2020. (Academic Treatise) https://www.sciencedirect.com/science/article/pii/B9780081029855000115 11. Mengru Cai, Liuying Qin, Longtai You, Yu Yao, Huimin Wu, Zhiqin Zhang, Lu Zhang* (co-corresponding), Xingbin Yin*, Jian Ni*. Functionalization of MOF-5 with Mono-Substituents: Effects on Drug Delivery Behavior. RSC Advances 2020, 10 (60), 36862-36872. (IF: 4.036) https://pubs.rsc.org/en/content/articlelanding/2020/ra/d0ra06106a 2019 12. Lu Zhang, Yanyu Huang, Aaron Raymond Lindstrom, Tzu-Yin Lin, Kit S Lam, Yuanpei Li*. Peptide-based materials for cancer immunotherapy. Theranostics 2019, 9 (25), 7807-7825. (IF: 11.6) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6831480/
2018 13. Lu Zhang#, Tinghui Yin#, Bo Li, Rongqin Zheng*, Chen Qiu, Kit S. Lam*, Qi Zhang, Xintao Shuai*. Size-Modulable Nanoprobe for High-Performance Ultrasound Imaging and Drug Delivery against Cancer. ACS Nano 2018, 12 (4), 3449-3460. (IF: 18.027) https://pubs.acs.org/doi/10.1021/acsnano.8b00076
14. Lu Zhang#, Di Jing#, Lei Wang, Yuan Sun, Jian Jian Li, Brianna Hill, Fan Yang, Yuanpei Li*, Kit S. Lam*. Unique Photochemo-Immuno-Nanoplatform against Orthotopic Xenograft Oral Cancer and Metastatic Syngeneic Breast Cancer. Nano Letters 2018, 18 (11), 7092-7103. (IF: 12.262) https://pubs.acs.org/doi/10.1021/acs.nanolett.8b03096
15. Hao Wu#, Lu Zhang#(co-first), Yuanpei Li*; Kit S. Lam*; Stimuli-Responsive Materials in Theranostics. Royal Society of Chemistry, 2018. (Academic Treatise) https://pubs.rsc.org/en/content/chapter/bk9781788011136-00284/978-1-78801-113-6 16. Hong Xiao, Jin He, Xiaoxia Li, Bo Li, Lu Zhang, Yong Wang*, Du Cheng, Xintao Shuai*. Polymeric Nanovesicles as Simultaneous Delivery Platforms with Doxorubicin Conjugation and Elacridar Encapsulation for Enhanced Treatment of Multidrug-Resistant Breast Cancer. Journal of Materials Chemistry B 2018, 6 (45), 7521-7529. (IF: 7.571) https://pubs.rsc.org/en/content/articlelanding/2018/TB/C8TB01829D 17. Yi Huang, Xiaoxia Li, Lu Zhang, Xiaoyan Chen, Chengbo Liu, Jingqin Chen, Yong Wanga*, XinTao Shuai. Multifunctional Nanoplatform Based on pH-responsive Micelle Coated with Discontinuous Gold Shell for Cancer Photothermo-chemotherapy and Photoacoustic Tomography. Chinese Journal of Polymer Science, 2018, 36, 1139-1149. (IF: 3.815) https://link.springer.com/article/10.1007/s10118-018-2141-8 2016 18. Yu Guo#, Jing Wang#, Lu Zhang#(co-first), Shunli Shen#, Ruomi Guo, Yang Yang*, Wenjie Chen, Yiru Wang, Guihua Chen*, Xintao Shuai*. Theranostical Nanosystem-Mediated Identification of An Oncogene and Highly Effective Therapy in Hepatocellular Carcinoma. Hepatology 2016, 63 (4), 1240-1255. (IF: 17.298) https://aasldpubs.onlinelibrary.wiley.com/doi/10.1002/hep.28409
19. Lu Zhang#, Hong Xiao#, Jingguo Li, Du Cheng*, Xintao Shuai*. Co-delivery of doxorubicin and arsenite with reduction and pH dual-sensitive vesicle for synergistic cancer therapy. Nanoscale 2016, 8 (25), 12608-12617. (IF: 8.307) https://pubs.rsc.org/en/content/articlelanding/2016/NR/C5NR07868G 20. Jingguo Li, Lu Zhang, Yujie Lin, Hong Xiao, Mingxiang Zuo, Du Cheng, Xintao Shuai*. A pH-Sensitive Prodrug Micelle Self-Assembled from MultiDoxorubicin-Tailed Polyethylene Glycol for Cancer Therapy. RSC Advances. 2016, 6 (11), 9160-9163. (IF: 4.036) https://pubs.rsc.org/en/content/articlelanding/2016/ra/c5ra2729 2014 21. Faming Gong, Zuoquan Zhang, Xiaodong Chen, Lu Zhang, Xingsu Yu, Qihua Yang, Xintao Shuai, Biling Liang*, Du Cheng*. A dual ligand targeted nanoprobe with high MRI sensitivity for diagnosis of breast cancer[J]. Chinese Journal of Polymer Science, 2014, 32 (3), 321-332. (IF: 3.815) https://link.springer.com/article/10.1007/s10118-014-1399-8 International patents 1) Kit S. Lam; Lu Zhang; Smart peptides and transformable nanoparticles for cancer immunotherapy, 2021-2-18, WIPO, PCT/US2020/046495. 2) Kit S. Lam; Lu Zhang; Cyanine-based telodendrimers and uses for treating cancer, 2020-5-3, WIPO, PCT/US2019/049080. Domestic patent 1）Xintao Shuai; Lu Zhang; Chen Qiu; Yi Huang; Mingxiang Zuo; Du Cheng; A kind of preparation method and application of pH and temperature dual sensitive nanovesicles，2016-07-12，CN201610548026.9 Clinical translational application 1) Dendrimer-encapsulated paclitaxel (PTX) nanomedicines for bladder cancer treatment have been approved by the US FDA for Phase I clinical studies (PEG5K-CA4-Porphyrin4, PLZ4 PEG5K-CA8, PTX). Clinical Translation Project No. 117888. 2) Developed a variety of GMP and GLP grade dendrimer polymers to encapsulate chemotherapeutics and immune drugs for nano-drugs, chemotherapeutic drugs (Doxorubicin, Paclitaxel, etc.), immune drugs (Resiquimod, Imiquimod, etc.); and have been approved for use in mice preclinical studies of bladder cancer, oral cancer, ovarian cancer and breast cancer models in animals such as rabbits, cats and dogs. The preclinical translation project numbers are 132838 and 135780, respectively. 1) National Cancer Institute (NCI), 1R01CA247685-01, HER2 targeting transformable nanotherapeutic platform against HER2+ cancers, 2020.02 - 2025.01, $572,096 (Each year). 2) Department of Defense (DOD), W81XWH-19-1-0204, Delivery of targeting nano-photo-imiquimod to greatly enhance check point blockade immunotherapy of patients with advanced bladder cancer, 2019.07 - 2023.06, $1,037,215 (Each year). 3) Department of Defense (DOD), W81XWH-19-1-0159, Novel nano-photo-immunotherapy against ovarian cancer, 2019.06 - 2022.06, $234,000 (Each year). 4) National Cancer Institute (NCI), 5R01CA115483-13, Therapeutic targeting agents for ovarian cancer, 2015.01 - 2021.04, $334,535 (Each year). 5) National Institute of Biomedical Imaging and Bioengineering (NIBIB), 2R01EB012569-09, Targeting nanotherapeutics against murine and feline oral cancer, 2010.12 - 2021.05, $518,074 (Each year). |
